SRZN - NASDAQ

Surrozen, Inc.

SRZN·NASDAQ

$24.57

+1.1%

HealthcareBiotechnology

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$183.72M

EPS-32.3700

P/E Ratio-0.76

Earnings Date08/06/2026

98.73M

Assets

104%

3Y+10.0%

5Y+59.0%

10Y+132.0%

286.49M

Total Liabilities

310%

3Y+2033.0%

5Y+1840.0%

10Y+2087.0%

-187.76M

Total Equity

778%

3Y-347.0%

5Y-497.0%

10Y-739.0%

Surrozen, Inc. Funding & Solvency Profile

SRZN · NASDAQ

Current Assets

Cash & Cash Equivalents89.25M

Net Receivables208.00K

Inventory0.00

Other Current Assets2.11M

Total Current Assets92 M

Non-Current Assets

Property, Plant & Equipment6.43M

Goodwill & Intangible Assets0.00

Long-Term Investments688.00K

Other Non-Current Assets46.00K

Total Non-Current Assets7 M

Total Assets

98.73M

Financial Health Analysis

Current Ratio

9.22x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Working Capital

82 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

93% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Surrozen, Inc. Balance Sheet

SRZN • NASDAQ

Surrozen, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	89.2M	34.6M	36M	24.7M	33.1M	35M	29.1M
Short-Term Investments	0.0	0.0	0.0	51.1M	68.8M	14.2M	0.0
Cash & Short-Term Investments	89.2M	34.6M	36M	75.8M	101.9M	49.2M	29.1M
Net Receivables	208K	2.5M	2.2M	2M	0.0	0.0	0.0
Accounts Receivables	208K	2M	2.2M	2M	0.0	0.0	0.0
Other Receivables	0.0	502K	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	1.2M	2.4M	2.7M	3.3M	1M	310K
Other Current Assets	2.1M	671K	580K	756K	0.0	0.0	0.0
Total Current Assets	91.6M	38.9M	41.1M	81.3M	105.2M	50.2M	29.4M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	6.4M	8.4M	3.9M	6.9M	9.4M	11.4M	12.6M
Long-Term Investments	688K	0.0	688K	0.0	21.7M	0.0	0.0
Other Non-Current Assets	46K	1.2M	402K	1.2M	954K	444K	454K
Total Non-Current Assets	7.2M	9.5M	4.9M	8.1M	32M	11.8M	13.1M
Total Assets	98.7M	48.5M	46.1M	89.4M	137.2M	62.1M	42.5M
LIABILITIES
CURRENT LIABILITIES
Total Payables	728K	306K	525K	658K	2.7M	1.8M	972K
Accounts Payable	728K	306K	525K	658K	2.7M	1.8M	972K
Accrued Expenses	0.0	5M	3.8M	6.3M	8.1M	3M	1.4M
Short Term Debt	1.3M	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	1.8M	2.5M	2.2M	2.2M	2.1M	1.5M
Other Current Liabilities	7.9M	191K	292K	581K	589K	416K	0.0
Total Current Liabilities	9.9M	7.3M	7.1M	9.7M	13.6M	7.3M	3.9M
NON-CURRENT LIABILITIES
Other Non-Current Liabilities	271.2M	55.9M	115K	326K	8.3M	0.0	0.0
Total Non-Current Liabilities	276.6M	62.5M	997K	3.7M	13.9M	7.5M	9.2M
Capital Lease Obligations	5.3M	8.5M	3.4M	5.6M	7.8M	9.6M	10.7M
Total Liabilities	286.5M	69.8M	8.1M	13.4M	27.5M	14.8M	13.1M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	83.2M
Common Stock	1K	0.0	0.0	0.0	4K	2K	1K
Additional Paid-In Capital	339.5M	263.9M	259.6M	254.9M	252.5M	135.3M	1.5M
Retained Earnings	-527.3M	-285.3M	-221.7M	-178.7M	-142.6M	-88M	-55.3M
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	-241K	-119K	0.0	0.0
Total Stockholders' Equity	-187.8M	-21.4M	37.9M	76M	109.7M	47.3M	29.4M
Total Equity	-187.8M	-21.4M	37.9M	76M	109.7M	47.3M	29.4M
SUMMARY
Total Liabilities & Equity	98.7M	48.5M	46.1M	89.4M	137.2M	62.1M	42.5M
Total Investments	688K	0.0	688K	51.1M	90.4M	14.2M	0.0
Total Debt	6.6M	8.5M	3.4M	5.6M	7.8M	9.6M	9.2M
Net Debt	-82.6M	-26.1M	-32.7M	-19.1M	-25.3M	-25.4M	-19.9M
Shares Outstanding	8,570,355	8,570,355	8,570,355	8,570,355	8,570,355	8,570,355	8,570,355

SEC Filings

SRZN - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 14, 2026	May 13, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 06, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 06, 2026	May 06, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 01, 2026	April 01, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 23, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 23, 2026	March 23, 2026	2026	View Filing
S-3 S-3 N/A	March 23, 2026	March 23, 2026		View Filing
8-K 8-K 2026 N/A	January 30, 2026	January 26, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 07, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 07, 2025	November 07, 2025	2025	View Filing

Showing 1 to 10 of 105 filings

Related Guides

Blog Categories

Continue your SRZN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.